FGF-21、CVAI在2型糖尿病肾病中的研究进展  

Research Progress of FGF-21 and CVAI in Type 2 Diabetic Kidney Disease

作　　者：才巴央宗 张惠莉[2] 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海大学附属医院内分泌与代谢科,青海 西宁

出　　处：《临床医学进展》2023年第7期12056-12061,共6页Advances in Clinical Medicine

摘　　要：2型糖尿病是一种异质病因的病理学,其特征是存在胰岛素抵抗、胰岛素分泌不足或两者兼而有之导致的高血糖,预计到2030年全球糖尿病患者人数约为4.39亿。糖尿病的延长与微血管有关,尤其是糖尿病肾病(DKD)。DKD是2型糖尿病最常见的并发症,是全球终末期肾病的主要原因。成纤维细胞生长因子21 (Fibroblast growth factor 21, FGF-21)是一种内分泌因子,参与机体物质代谢、维持脂肪和糖代谢的平衡。近年来研究发现FGF-21在糖尿病肾病(DKD)患者中呈异常高表达,且对DKD有较高的诊断价值。腹型肥胖被认为是心脏疾病、代谢疾病、糖尿病、和糖尿病并发症的重要危险因素之一。最近一项新的调查研究提示在中国成人糖尿病患者中,内脏脂肪指数(VAI)和中国人内脏脂肪指数(CVAI)与肾病的发生独立相关。本文对FGF-21、CVAI与糖尿病肾病相关性进行综述。Type 2 diabetes mellitus, a heteroetiological pathology characterized by hyperglycemia due to insu-lin resistance, inadequate insulin production, or both, is estimated to affect 439 million people worldwide by 2030. Prolongation of diabetes is associated with microvessels, especially diabetic kidney disease (DKD). DKD is the most common complication of type 2 diabetes and the leading cause of end-stage renal disease worldwide. Fibroblast growth factor 21 (Fibroblast growth factor 21, FGF-21) is a kind of endocrine factor, involved in the body’s metabolism, maintaining the bal-ance of metabolism of fat and sugar. Recent studies have found that FGF-21 is abnormally highly expressed in patients with diabetic kidney disease (DKD), and has high diagnostic value for DKD. Abdominal obesity is considered to be an important risk factor for heart disease, metabolic disease, diabetes, and diabetes complications. A new study suggests that visceral fat index (VAI) and Chinese visceral fat index (CVAI) are independently associated with the development of kidney disease in Chinese adults with diabetes. This paper reviews the correlation between FGF-21, CVAI and diabetic nephropathy.

关 键 词：FGF-21 CVAI 2型糖尿病 糖尿病肾病 胰岛素抵抗 

分 类 号：R58[医药卫生—内分泌]